好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Longitudinal Investigation of Retrograde Transsynaptic Degeneration in Multiple Sclerosis and Its Association with Clinical Characteristics and Visual Field Deficits
Multiple Sclerosis
P11 - Poster Session 11 (8:00 AM-9:00 AM)
1-002
To assess longitudinal changes in a quantitative index measuring rTSD severity (rTSD index), clinical predictors of longitudinal rTSD index changes,  and its impact on visual hemifield deficits longitudinally.

Retrograde trans-synaptic degeneration (rTSD) of the visual pathway has been described in people with MS (pwMS) and is characterized by hemi macular retinal ganglion cell degeneration in connection with posterior visual pathway lesions. Longitudinal studies examining the rate of rTSD in pwMS and its association with clinical characteristics and visual outcomes are lacking.

In this single center longitudinal study, pwMS underwent clinical assessments, OCT imaging, and perimetry evaluation at baseline and 1 year follow up rTSD index values were analyzed from OCT data and mean visual hemifield defect differences corresponding to the rTSD index values were calculated. Predictors of longitudinal changes in rTSD index were assessed using multivariate linear regression. The association between longitudinal mean hemifield defect and rTSD index changes over time were assessed using multivariate linear regression adjusting for baseline age and stratified by history of optic neuritis (ON).

A total of 30 pwMS were included (mean age 46.2 ±14; 63% females; 26 RRMS and 4 progressive MS). An increase in absolute rTSD index, indicating worsening retinal trans-synaptic neurodegeneration, was significantly associated with female sex (β =1.36, p=0.001), progressive MS (β =0.94, p=0.01), and dyslipidemia history (β =1.45, p=0.001) . On average, mean hemifield defects worsened by 0.41 dB for each unit increase in rTSD index after adjusting for baseline age in pwMS without ON history (Beta=0.41,p=0.019), but was not significant in pwMS with ON history.

Longitudinal worsening of rTSD of the visual pathway in pwMS can be quantified using rTSD index values and is associated with progressive MS subtype, and worsening visual deficits in the corresponding hemifield.

Authors/Disclosures
Abdul Jaber Tayem, MD
PRESENTER
Dr. Tayem has nothing to disclose.
Angel Liu Ms. Liu has nothing to disclose.
Gabriela Zabala (Cedars Sinai) No disclosure on file
Sargis Manukyan Mr. Manukyan has nothing to disclose.
Laura M. Locke, NP (Cedars Sinai) Ms. Locke has nothing to disclose.
Paula Barreras, MD (Cedars-Sinai Medical Center) Dr. Barreras has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. The institution of Dr. Barreras has received research support from Foundation for Sarcoidosis Research. The institution of Dr. Barreras has received research support from 好色先生.
Marwa Kaisey, MD (Cedars-Sinai Medical Center) Dr. Kaisey has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG therapeutics. Dr. Kaisey has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics. Dr. Kaisey has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biogen. Dr. Kaisey has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Genentech. Dr. Kaisey has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for TG Therapeutics. The institution of Dr. Kaisey has received research support from NMSS.
Nancy L. Sicotte, MD, FAAN (Cedars-Sinai Medical Center) The institution of Dr. Sicotte has received research support from PCORI. The institution of Dr. Sicotte has received research support from NIH. The institution of Dr. Sicotte has received research support from NMSS. Dr. Sicotte has a non-compensated relationship as a National Medical Advisory Committee Chair with National MS Society that is relevant to AAN interests or activities.
Pascal Sati (Cedars Sinai) The institution of Pascal Sati has received research support from National Multiple Sclerosis Society. The institution of Pascal Sati has received research support from National Institutes of Health . The institution of Pascal Sati has received research support from Erwin Rautenberg Fondation. The institution of Pascal Sati has received research support from Department of Defense. Pascal Sati has received intellectual property interests from a discovery or technology relating to health care. Pascal Sati has received publishing royalties from a publication relating to health care.
Omar Al-Louzi, MD (Cedars-Sinai Medical Center) The institution of Dr. Al-Louzi has received research support from the National Multiple Sclerosis Society and American Brain Foundation. The institution of Dr. Al-Louzi has received research support from the Department of Defense.